GLP1 to GIP and Amylin...Evolving Obesity Treatment through Multi-Hormone-Based Treatment
Sep 15, 2025
|
Gross Research announced the results of an analysis of the global next-generation obesity treatment industry through a regular report in September. This 'Multi-Hormone Industry Analysis Report' comprehensively contains clinical data, mechanism differentiation, and market size prospects of major global companies. In particular, it focused on multi-hormone-based treatment strategies that target multiple hormones such as GLP-1, GIP, and amylin at the same time, breaking away from the existing GLP-1 single agent-centered structure.
According to the report, Novo Nordisk's Semaglutide (Wigobi, Ozempic) and Eli Lilly's Tirzepatide (Mounjaro, Jebbound) are currently leading the global market. However, tolerability issues continue to be raised due to the once-a-week administration method, structural limitations of GLP-1 alone, and gastrointestinal side effects such as nausea and vomiting.
As an alternative to this, global pharmaceutical companies are starting a multi-hormone approach in earnest. Eli Lilly demonstrated superior weight loss effects compared to conventional drugs through Retatrutide (GLP-1/GIP/GCGR triple agent), suggesting a potential for weight loss of more than 25% in the long run. Through Maritide, Amgen is attempting to control GIP receptors with partial inhibition strategies rather than simple activation, thereby suppressing fat accumulation and optimizing appetite control.
Amylin-based strategies are also emerging. Amylin, secreted along with insulin, is a hormone involved in appetite suppression and gastric emptying delay, and there is a movement to strengthen the therapeutic effect through combination with GLP-1 or development of double agents. Significant weight loss results have also been reported in early clinical trials.
In addition, U.S. biotech company Metcera is expanding its technological competitiveness by securing a pipeline that extends to once-a-monthly administered GLP-1 (M097i), amylin (M4: GLP-1+GIP+GCGR+Amylin), and oral formulation (Oralink).
Han Yong-hee, CEO of Groth Research, said, "Multi-hormone-based treatments will be a game changer that goes beyond simple weight loss to improve patients' quality of life and long-term treatment duration. New challenges and opportunities are being opened not only to global pharmaceutical companies but also to domestic companies with technological prowess."." The obesity treatment market has already grown explosively due to the success of GLP-1 injections, but multi-hormone and oral formulations will be two pillars of industrial evolution in the future, he predicted.
This article was translated by Naver AI translator.
